Developing new drugs to fight tuberculosis.
Official title: Optimization of novel inhibitors of mycolic acid synthesis as TB drug candidates.
Funded at University of Central Florida · NIH-10948553 · Data updated 2026-11-12
This study is working on new medicines to help fight tuberculosis by targeting a specific part of the bacteria that causes it, with the goal of finding better treatments that work even against tough, drug-resistant strains.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Central Florida NIH-funded |
| Lab location | 1 site (Orlando, United States) |
| Project start | July 17, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $237,288 |
| NIH project number | 1R21AI185841-01 |
| Project ID | NIH-10948553 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with tuberculosis, especially those who have drug-resistant strains or have difficulty tolerating current treatments.
✕Less likely to help
Patients with non-tuberculosis related respiratory conditions or those who are not infected with Mycobacterium tuberculosis may not benefit from this research.
What this research studies
This research focuses on creating novel inhibitors that target mycolic acid synthesis in the bacteria causing tuberculosis (TB). By understanding the different states of the bacteria and their environments, the research aims to develop more effective antibiotic treatments that can overcome the limitations of current therapies. The approach includes testing various drug combinations to ensure they can effectively kill the bacteria while minimizing resistance. This is particularly important given the rising challenge of multidrug-resistant TB strains.
Why it matters
Potential benefit: If successful, this research could lead to more effective and shorter treatment options for tuberculosis, improving patient outcomes and reducing the burden of the disease.
How similar studies have gone: Previous research has shown promise in developing new antibiotics targeting mycobacterial infections, indicating that this approach has potential for success.
Where this research is happening
-
University of Central Florida
Orlando, United States Active
Researchers
- Principal investigator: Rohde, Kyle H — University of Central Florida
- Study coordinator: Rohde, Kyle H
Related research
Other NIH-funded projects on the same topics.
-
Sexually Transmitted Infection Testing Risk and Prevention among Trans Women
A study to improve STI testing and prevention for trans women by testing self-collection vs clinician collection, and by measuring STI prevalence across sites and how social factors influence risk.
-
Collaborative AI for safer, faster bacteremia care
A physician-centered AI system is being built to help diagnose and treat bloodstream infections more accurately and safely, with the goal of reducing sepsis deaths.
-
Bayesian data tools to map and fight syphilis and congenital syphilis
A data-driven, bayesian approach will turn messy health data into clear, local-level insights to prevent congenital syphilis and reduce syphilis in communities.
-
Harnessing neuron-derived vesicles to find Huntington’s disease biomarkers
A research project aims to identify brain-derived biomarkers in blood that reflect Huntington disease activity, using neuronal extracellular vesicles as the signal source.
-
Heart nerves: mapping how the heart’s sensing nerves connect in health and diabetes
This project maps the nerve pathways that sense heart signals in healthy and diabetic hearts to identify targets for therapies that could reduce heart injury.
-
Strengths-based suicide prevention for Black sexual minority youth
A research project aims to help Black sexual minority youth reduce suicidal thoughts and behaviors by understanding protective factors and risks in everyday life.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.